Alcon has announced the commercial availability of its Voyager direct selective laser trabeculoplasty (DSLT) device in the United States. The device, which is controlled through a touchscreen, is the first contactless laser for glaucoma and eliminates the need for manual aiming and reducing specialized training requirements. The GLAUrius trial found that DSLT effectively controls intraocular pressure with a low risk of adverse events. The device received 510(k) clearance from the U.S. FDA in late 2023 and is also available in certain markets in the European Union and United Kingdom.

Source: Ophthalmology Management